Join our daily newsletter At The Bell to receive exclusive market insights
- Recce Pharmaceuticals (RCE) appoints Dr Philip Sutton as Vice President of Translational Sciences
- This role will take responsibility for advancing the company’s compounds across a portfolio of infectious disease programs with unmet medical needs
- Dr Sutton has been involved with Recce since August 2020, when he investigated the potential of the company’s anti-infectives across multiple pre-clinical programs
- Prior to this, he was Head of Immunology at CSL (CSL) in Melbourne and has co-authored 99 peer-reviewed publications
- Shares are trading steady at 80 cents at 2:07 pm AEST
Recce Pharmaceuticals (RCE) has appointed Dr Philip Sutton as Vice President of Translational Sciences.
Within this role, Dr Sutton will work to advance the company’s compounds across a portfolio of infectious disease programs with unmet medical needs.
He has been involved with Recce since August 2020, when he investigated the potential of the company’s anti-infectives across multiple pre-clinical programs.
Prior to this, he was Head of Immunology at CSL (CSL) in Melbourne and has co-authored 99 peer-reviewed publications.
CEO James Graham said he was pleased with the appointment.
“Dr Sutton joins us at an exciting time as our clinical programs continue to advance and welcome his contributions to the pipeline development of our new class of anti-infectives,” he said.
Shares were trading steady at 80 cents at 2:07 pm AEST.
